1. Home
  2. EMPD vs ACET Comparison

EMPD vs ACET Comparison

Compare EMPD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Empery Digital Inc.

EMPD

Empery Digital Inc.

HOLD

Current Price

$2.99

Market Cap

92.5M

Sector

N/A

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$9.54

Market Cap

83.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMPD
ACET
Founded
2020
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.5M
83.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
EMPD
ACET
Price
$2.99
$9.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
458.5K
74.1K
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
94.47
N/A
EPS
N/A
N/A
Revenue
$974,977.00
N/A
Revenue This Year
$23.49
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.48
$0.46
52 Week High
$8.17
$9.97

Technical Indicators

Market Signals
Indicator
EMPD
ACET
Relative Strength Index (RSI) 48.38 58.39
Support Level $2.64 $7.45
Resistance Level $3.15 $9.59
Average True Range (ATR) 0.25 0.52
MACD 0.03 0.05
Stochastic Oscillator 32.09 66.67

Price Performance

Historical Comparison
EMPD
ACET

About EMPD Empery Digital Inc.

Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: